These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 23928465

  • 1. Enhancement of antigen-specific CD8 T cell responses by co-delivery of Fc-fused CXCL11.
    Namkoong H, Song MY, Seo YB, Choi DH, Kim SW, Im SJ, Sung YC, Park Y.
    Vaccine; 2014 Feb 26; 32(10):1205-12. PubMed ID: 23928465
    [Abstract] [Full Text] [Related]

  • 2. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1.
    Song MY, Park SH, Nam HJ, Choi DH, Sung YC.
    J Immunother; 2011 Apr 26; 34(3):297-306. PubMed ID: 21389868
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH, Jin HT, Park SH, Youn JI, Sung YC.
    Vaccine; 2009 Sep 25; 27(42):5906-12. PubMed ID: 19651174
    [Abstract] [Full Text] [Related]

  • 5. Flagellin enhances tumor-specific CD8⁺ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model.
    Nguyen CT, Hong SH, Sin JI, Vu HV, Jeong K, Cho KO, Uematsu S, Akira S, Lee SE, Rhee JH.
    Vaccine; 2013 Aug 20; 31(37):3879-87. PubMed ID: 23831323
    [Abstract] [Full Text] [Related]

  • 6. Wrinkle in the plan: miR-34a-5p impacts chemokine signaling by modulating CXCL10/CXCL11/CXCR3-axis in CD4+, CD8+ T cells, and M1 macrophages.
    Hart M, Nickl L, Walch-Rueckheim B, Krammes L, Rheinheimer S, Diener C, Taenzer T, Kehl T, Sester M, Lenhof HP, Keller A, Meese E.
    J Immunother Cancer; 2020 Nov 20; 8(2):. PubMed ID: 33229509
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine.
    Karan D, Krieg AM, Lubaroff DM.
    Int J Cancer; 2007 Oct 01; 121(7):1520-8. PubMed ID: 17565748
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
    Park JY, Jin DH, Lee CM, Jang MJ, Lee SY, Shin HS, Chung YH, Kim KY, Kim SS, Lee WB, Shin YK, Lee WJ, Park YM, Kim D.
    J Immunother; 2010 Jun 01; 33(5):510-22. PubMed ID: 20463596
    [Abstract] [Full Text] [Related]

  • 14. Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C).
    Wick DA, Martin SD, Nelson BH, Webb JR.
    Vaccine; 2011 Jan 29; 29(5):984-93. PubMed ID: 21115055
    [Abstract] [Full Text] [Related]

  • 15. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis.
    Hensbergen PJ, Wijnands PG, Schreurs MW, Scheper RJ, Willemze R, Tensen CP.
    J Immunother; 2005 Jan 29; 28(4):343-51. PubMed ID: 16000952
    [Abstract] [Full Text] [Related]

  • 16. Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity--a tale of conflict and conundrum.
    Müller M, Carter S, Hofer MJ, Campbell IL.
    Neuropathol Appl Neurobiol; 2010 Aug 29; 36(5):368-87. PubMed ID: 20487305
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Strong immune responses induced by a DNA vaccine containing HPV16 truncated E7 C-terminal linked to HSP70 gene.
    Meshkat Z, Soleimanjahi H, Mirshahabi H, Meshkat M, Kheirandish M, Hassan ZM.
    Iran J Immunol; 2011 Jun 29; 8(2):65-75. PubMed ID: 21705833
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis.
    Basset L, Chevalier S, Danger Y, Arshad MI, Piquet-Pellorce C, Gascan H, Samson M.
    J Mol Med (Berl); 2015 Dec 29; 93(12):1355-67. PubMed ID: 26199110
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.